Douglas Blankenship
Keine laufenden Positionen mehr
Profil
Mr. Douglas L.
Blankenship is a Chief Financial Officer at Holdco Nuvo Group DG Ltd.
Mr. Blankenship was previously employed as a CFO & Principal Accounting Officer by Dova Pharmaceuticals, Inc., a Director-Global Quality & Compliance by Roche Pharmaceuticals, Inc., a Finance Director by Amgen Technology (Ireland) Unlimited Co., a Director-Global Quality, Compliance & Technical by Genentech, Inc., and a Chief Financial Officer by Humacyte, Inc. /Old/.
He received his undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Wharton School of the University of Pennsylvania.
Aktive Positionen von Douglas Blankenship
Unternehmen | Position | Beginn |
---|
Ehemalige bekannte Positionen von Douglas Blankenship
Unternehmen | Position | Ende |
---|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Finanzdirektor/CFO | 19.05.2021 |
DOVA PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 31.01.2018 |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Compliance Officer | 01.10.2015 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.10.2015 |
Amgen Technology (Ireland) Unlimited Co.
Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Finanzdirektor/CFO | 01.01.2008 |
Ausbildung von Douglas Blankenship
California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Amgen Technology (Ireland) Unlimited Co.
Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Health Services |